75 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
(such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's
8-K
EX-99.1
j4bx9x6
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
3b4cwqgxa6gq262oqac8
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T/A
EX-99
ml2vl2
25 Sep 23
Third party tender offer statement (amended)
8:48am
SC TO-T
EX-99
vqpbs u9u
25 Aug 23
Third party tender offer statement
7:46am
SC TO-C
EX-99.2
iglby9 ci21
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
EX-99.1
mjtv623bd8em6ztmbl5
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
rj0fs4wx3mqpxhm5ndth
9 Aug 23
Information about tender offer
4:15pm
8-K
EX-99.1
1nints
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
v8j076waxj 7nv56
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am